#1 Clinical Trials Search in Europe

Pentixather

Pentixather, a promising drug in cancer treatment, is currently being studied in various clinical trials. These trials aim to evaluate its safety, efficacy, and potential applications in treating different types of cancer, including lung carcinoids, multiple myeloma, central nervous system lymphoma, and acute leukemia. The drug targets the CXCR4 receptor, which is overexpressed in many cancer cells, making it a potential game-changer in cancer therapy.

Table of Contents

What is PENTIXATHER?

PENTIXATHER is an innovative drug being studied for the treatment of various types of cancer. It belongs to a class of medications called radioligand therapies, which combine a targeting molecule with a radioactive substance to deliver radiation directly to cancer cells[1]. PENTIXATHER is designed to target a specific protein called CXCR4, which is found in high levels on many types of cancer cells[2].

The drug can be labeled with different radioactive isotopes for various purposes:

  • 68Ga-Pentixather: Used for diagnostic imaging (PET/CT scans) to locate cancer cells[2]
  • 177Lu-Pentixather or 90Y-Pentixather: Used for treatment to deliver radiation directly to cancer cells[3]
  • 212Pb-Pentixather: An experimental version using alpha radiation for treatment[1]

How Does PENTIXATHER Work?

PENTIXATHER works by targeting a protein called CXCR4, which is often overexpressed (present in higher than normal amounts) on cancer cells. The drug attaches to this protein and delivers radioactive particles directly to the cancer cells. This targeted approach allows for more precise treatment of cancer while potentially reducing damage to healthy tissues[2].

The mechanism of action can be broken down into two steps:

  1. Targeting: The PENTIXATHER molecule seeks out and binds to CXCR4 proteins on cancer cells.
  2. Radiation delivery: Once bound, the radioactive component of PENTIXATHER emits radiation, damaging the DNA of cancer cells and potentially killing them.

What Conditions Can PENTIXATHER Treat?

PENTIXATHER is being studied for the treatment of several types of cancer, including:

  • Multiple Myeloma: A type of blood cancer that affects plasma cells in the bone marrow[2]
  • Lung Carcinoids and Neuroendocrine Carcinomas: Rare types of lung cancer[1]
  • Central Nervous System (CNS) Lymphoma: A type of cancer that affects the brain and spinal cord[3]
  • Acute Leukemia: A group of fast-progressing blood cancers[4]

These conditions have been chosen for study because they often express high levels of the CXCR4 protein, making them potential targets for PENTIXATHER therapy.

Current Clinical Trials

Several clinical trials are currently underway to evaluate the safety and effectiveness of PENTIXATHER in different cancer types:

  • A study using 212Pb-Pentixather for lung carcinoids and neuroendocrine carcinomas[1]
  • A comparison of 68Ga-Pentixather and 68Ga-Pentixafor for imaging in multiple myeloma patients[2]
  • A trial of 90Y-Pentixather for CNS lymphoma[3]
  • A study of 177Lu-Pentixather for relapsed or refractory acute leukemia[4]

These trials are in various phases, from early safety studies (Phase 1) to later-stage efficacy studies (Phase 2). They aim to determine the optimal dose, safety profile, and effectiveness of PENTIXATHER in treating these cancers.

How is PENTIXATHER Administered?

PENTIXATHER is typically administered as an intravenous (IV) injection. The exact procedure may vary depending on the specific study and form of PENTIXATHER being used, but generally involves the following steps:

  1. Imaging: Patients may first undergo a PET/CT scan using a diagnostic version of PENTIXATHER to confirm the presence of CXCR4-expressing tumors and plan treatment[1].
  2. Preparation: Some protocols may include pre-medication or kidney protection measures[1].
  3. Injection: The therapeutic version of PENTIXATHER is administered via IV infusion.
  4. Monitoring: Patients are closely monitored after injection, with follow-up scans and blood tests to assess response and safety[3].

The frequency and number of treatments can vary. Some studies involve a single dose, while others may use multiple cycles spaced several weeks apart[1].

Safety and Side Effects

As PENTIXATHER is still in clinical trials, its full safety profile is not yet established. However, potential side effects are being closely monitored in all studies. Some possible side effects may include:

  • Fatigue
  • Nausea
  • Changes in blood cell counts
  • Kidney or liver function changes

The trials are designed to carefully assess the safety of PENTIXATHER, including monitoring for dose-limiting toxicities and any adverse events[3][4]. Patients in these trials undergo regular check-ups, blood tests, and imaging to ensure their safety throughout the treatment process.

Future Prospects

PENTIXATHER represents a promising new approach in cancer treatment, offering the potential for highly targeted therapy for cancers that express the CXCR4 protein. If successful in clinical trials, it could provide a new option for patients with difficult-to-treat cancers or those who have not responded to other therapies.

The ongoing research aims to:

  • Determine the most effective and safest doses of PENTIXATHER
  • Identify which patients are most likely to benefit from this treatment
  • Explore combinations with other cancer therapies
  • Expand the use of PENTIXATHER to other types of cancer that express CXCR4

As research progresses, PENTIXATHER may become an important tool in the fight against various types of cancer, offering hope for improved outcomes and quality of life for patients.

Aspect Details
Drug Name Pentixather
Target CXCR4 receptor
Cancer Types Studied Lung carcinoids, Multiple myeloma, CNS lymphoma, Acute leukemia
Administration Intravenous injection
Radioactive Labels Lead-212, Yttrium-90, Lutetium-177
Study Phases Phase I/II
Primary Outcomes Safety, tolerability, maximum tolerated dose
Secondary Outcomes Efficacy, response rates, progression-free survival, overall survival
Imaging Techniques PET/CT, SPECT/CT
Unique Feature Theranostic approach (combined diagnosis and therapy)

FAQ

  • What is Pentixather and how does it work? Pentixather is a drug that targets the CXCR4 receptor, which is often overexpressed in cancer cells. It can be labeled with radioactive isotopes like lead-212, yttrium-90, or lutetium-177 for imaging and treatment purposes. This allows for targeted radiation delivery to cancer cells while minimizing damage to healthy tissues.
  • What types of cancer are being studied with Pentixather? Clinical trials are currently investigating Pentixather for various cancers, including atypical lung carcinoids, neuroendocrine tumors, multiple myeloma, central nervous system lymphoma, and acute leukemia.
  • How is Pentixather administered to patients? Pentixather is typically administered through intravenous injection. The exact dosage and frequency may vary depending on the specific trial and cancer type being studied.
  • What are the potential benefits of Pentixather treatment? Pentixather offers the potential for targeted cancer treatment, which may lead to improved efficacy and reduced side effects compared to traditional therapies. It also allows for both diagnostic imaging and therapy, known as a theranostic approach.
  • Are there any known side effects of Pentixather? As with any medical treatment, there may be side effects. The clinical trials are designed to assess the safety and tolerability of Pentixather. Potential side effects may include impacts on bone marrow, kidneys, and other organs. The trials closely monitor patients for any adverse events.

Ongoing Clinical Trials on Pentixather

  • Study on the Safety and Effectiveness of [90Y]Y-PentixaTher in Patients with Recurrent or Resistant CNS Lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of [90Y]Y-PentixaTher and [68Ga]Ga-PentixaFor in patients with advanced Non-Hodgkin lymphomas: Evaluating radiopeptide-based imaging and therapy

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • CXCR4: A protein found on the surface of some cells, including cancer cells. It plays a role in cell migration and is often overexpressed in various types of cancer.
  • Radioligand therapy: A type of cancer treatment that uses a radioactive substance attached to a drug that targets specific cancer cells.
  • PET/CT: Positron Emission Tomography/Computed Tomography, an imaging technique that combines PET and CT scans to provide detailed pictures of the body's structures and functions.
  • Theranostics: An approach that combines diagnostic imaging and therapy, allowing for personalized treatment based on specific characteristics of a patient's disease.
  • Dose-limiting toxicity: Side effects of a treatment that are severe enough to prevent an increase in the dose or require a dose reduction.
  • Maximum tolerated dose: The highest dose of a drug or treatment that does not cause unacceptable side effects.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall response rate: The percentage of patients whose cancer shrinks or disappears after treatment.
  • Minimal residual disease: Small numbers of cancer cells that remain in the body during or after treatment.

References

  1. https://clinicaltrials.gov/study/NCT05557708
  2. https://clinicaltrials.gov/study/NCT05364177
  3. https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-90yy-pentixather-in-patients-with-recurrent-or-resistant-cns-lymphoma/
  4. https://clinicaltrials.gov/study/NCT06356922